ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies
30 avr. 2024 07h00 HE
|
ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 30, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
09 avr. 2024 07h00 HE
|
ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 09, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc.(Nasdaq: PMN), a biotechnology company focused on the generation and development of...
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April
04 avr. 2024 07h00 HE
|
ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 04, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
01 avr. 2024 16h15 HE
|
ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, April 01, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and...
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio
11 mars 2024 07h00 HE
|
ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, March 11, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference
22 févr. 2024 07h00 HE
|
ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
22 janv. 2024 07h00 HE
|
ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 22, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
ProMIS Neurosciences Issues Letter to Shareholders
08 janv. 2024 07h00 HE
|
ProMIS Neurosciences Inc.
TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues Letter to ShareholderProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company...
ProMIS Neurosciences, Inc. Announces Leadership Transition
03 janv. 2024 07h00 HE
|
ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of...
ProMIS Neurosciences Announces Publication on Novel Target for ALS
20 déc. 2023 07h00 HE
|
ProMIS Neurosciences Inc.
Study results published in Acta Neuropathologica Communications support targeting of RACK1 as a potential therapeutic approach for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar...